Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Abstract: Modular conduit systems in which a plurality of tubular link components are interconnected to form a continuous conduit. Each adjacent pair of tubular link components has a ball-and-socket joint that enables the pair of tubular link components to be pivoted with respect to each other. The ball-and-socket joint consists of a ball attached to a first one of the pair of adjacent tubular link components and a socket attached to a second one of the pair of adjacent tubular link components, where the ball is positioned within the socket. The amount of friction between the ball and the socket is adjustable, so that the amount of force required to pivot the pair of tubular link components with respect to each other, which is dependent upon the amount of friction between the ball and the socket, is variable.

Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Abstract: Modular conduit systems in which a plurality of tubular link components are interconnected to form a continuous conduit. Each adjacent pair of tubular link components has a ball-and-socket joint that enables the pair of tubular link components to be pivoted with respect to each other. The ball-and-socket joint consists of a ball attached to a first one of the pair of adjacent tubular link components and a socket attached to a second one of the pair of adjacent tubular link components, where the ball is positioned within the socket. The amount of friction between the ball and the socket is adjustable, so that the amount of force required to pivot the pair of tubular link components with respect to each other, which is dependent upon the amount of friction between the ball and the socket, is variable.

Abstract: A MEMS sensor includes a micro-electromechanical structure, a detection circuit, and a self-test circuit to test the health of the MEMS sensor during runtime operations. The self-test circuit is configured to inject into the micro-electromechanical structure a plurality of injected test signals that are broad-band frequency-varying frequency signals, which are based on spread spectrum based modulation. The injected test signals may a magnitude that is below an observable threshold of the sensor signal as well as a test-signal bandwidth that overlaps with a substantial portion of the sensor bandwidth, including the stimulus of interest.

Abstract: Systems and methods for lighting body panels of automobiles to facilitate repair of the body panels, where one embodiment is a portable lighting apparatus that includes a light board, a base and an extension member that connects the light board to the base. The light board is supported by the extension member, which is supported by the base. A battery in the base provides power through conductors in the extension member to light sources in the light board. The extension member has a conduit that holds the conductors therein and can rotate, thereby allowing the light board to rotate with respect to the base. A suction cup mount on the base enables the base to be secured to an automobile body panel, and the extension member allows the light board to be positioned as desired.

Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Abstract: Systems and methods for lighting body panels of automobiles to facilitate repair of the body panels, where one embodiment is a portable lighting apparatus that includes a light board, a base and an extension member that connects the light board to the base. The light board is supported by the extension member, which is supported by the base. A battery in the base provides power through conductors in the extension member to light sources in the light board. A slip ring in the extension member couples the conductors together so that they can rotate, thereby allowing the light board to rotate with respect to the base, without twisting the conductors. A suction cup mount on the base enables the base to be secured to an automobile body panel, and the extension member allows the light board to be positioned as desired.

Abstract: A method of detecting activity with a MEMS accelerometer stores a value of acceleration, then measures acceleration at a later time, calculates a change in acceleration using the measured acceleration and the stored acceleration, and compares the change in acceleration to an activity threshold to detect activity. A method of detecting inactivity uses a similar technique along with a timer. The method of detecting inactivity with a MEMS accelerometer stores an acceleration value, then measures acceleration at a later time, calculates a change in acceleration using the measured acceleration and the stored acceleration, and compares the change in acceleration to an inactivity threshold. If the change in acceleration is less than the inactivity threshold and, if a predetermined period of time has elapsed, then inactivity is detected.

Abstract: A wedge is used to engage on one side with a femoral tunnel or a tibial tunnel and on the opposite side engage with a bone plug. This is accomplished by forming a wedge being substantially semi-circular on one side and flat on the opposite side.

Abstract: Systems and methods for lighting body panels of automobiles to facilitate repair of the body panels, where one embodiment is a portable lighting apparatus that includes a light board, a base and an extension member that connects the light board to the base. The light board is supported by the extension member, which is supported by the base. A battery in the base provides power through conductors in the extension member to light sources in the light board. A slip ring in the extension member couples the conductors together so that they can rotate, thereby allowing the light board to rotate with respect to the base, without twisting the conductors. A suction cup mount on the base enables the base to be secured to an automobile body panel, and the extension member allows the light board to be positioned as desired.